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Abstract 
Objective: To investigate the molecular cause of persistent fevers in a patient returning from 
working overseas, in whom investigations for tropical diseases were negative.  
Methods: DNA was extracted from whole blood, , leukocyte subpopulations, saliva, hair root 
and sperm. The TNFRSF1A gene was analysed by polymerase chain reaction (PCR), allele 
specific (AS)-PCR, Sanger-sequencing and, next-generation sequencing.  In silico molecular 
modelling was performed to predict the structural and functional consequences to the 
extracellular domain of the mutant TNFR1 protein.  
 Results: Sanger sequencing corroborated by AS-PCR detected a novel in-frame deletion of 
24 nucleotides (c.255_278del) in the TNFRSF1A gene which was subsequently confirmed by 
the next-generation sequencing methods (targeted sequencing and amplicon-based deep 
sequencing). The latter  revealed variable frequency of the mutant allele among different cell 
lines including sperm, supporting the presence of gonosomal TNFRSF1A mosaicism. The 
patient had a complete response to treatment with IL-1 blockade, with resolution of 
symptoms and normalization of acute phase proteins.   
Conclusion:  
We describe the first case of gonosomal TNFRSF1A mosaicism in TRAPS due to a novel, 
somatic 24 nucleotide in-frame deletion. The clinical picture including complete response to 
IL-1 blockade were typical for TRAPS. This case adds TRAPS to the list of dominantly 
inherited autoinflammatory diseases reported to be caused by somatic (or postzygotic)  
mutation.  
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Introduction 
 
TNF Receptor - Associated Periodic Syndrome (TRAPS) is an autosomal dominant disease 
caused by gain-of-function mutations in the TNF superfamily receptor 1A (TNFRSF1A) (1) 
gene encoding the 55 kDa TNF receptor type I (TNFR1). TRAPS was initially described in 
1982 in an Irish-Scottish family with a 'periodic disease' complicated by AA amyloidosis (2). 
Subsequently it has been reported in different ethnic groups including Caucasians, Black 
Americans, Japanese and subjects of Mediterranean ancestry (3-5). The disease is 
characterized by episodes of fever accompanied by severe abdominal pain, arthralgia, 
migratory  myalgia, rash, chest pain, lymphadenopathy, ocular inflammation, and periorbital 
swelling. The duration of the attacks can range from a few days to several weeks or more, 
with onset from early childhood to adulthood. During febrile episodes, patients with TRAPS 
demonstrate elevation of C-reactive protein (CRP) and serum amyloid A protein (SAA) and 
are at high risk of developing AA amyloidosis (6, 7). 
TNFR1 belongs to a death domain superfamily and contains an extracellular motif 
containing four cysteine-rich domains (CRDs), a transmembrane domain, and an intracellular 
death domain. Binding of TNFα to the extracellular region of TNFR1 results in trimerisation 
of the receptor and activation of NF-kappa B, leading to either inflammation or apoptosis.  
The mechanisms by which over known 100 mutations in TNFRSF1A gene induce TRAPS 
remains to be fully elucidated, but are currently thought to be largely associated with 
endoplasmic reticulum stress due to retention of misfolded protein (8). It is well recognised 
that the disease phenotype varies with respect to the age at disease onset, duration and 
severity of the febrile episodes as well as risk of developing AA amyloidosis (7). Although 
earlier series suggested that mutations affecting extracelluar cysteine residues and the 
p.T50M variant were associated with more severe disease and a higher risk of serious 
complications, this has not been supported by the recent large Eurofevers series (7). 
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Here we report a patient with the TRAPS phenotype, in whom we identified a novel 24 
nucleotide in frame deletion in the TNFRSF1A gene. The mutant allele frequency (MAF) 
varied among different cell populations, including sperm, indicating findings consistent with  
gonosomal TNFRSF1A  mosaicism. IL-1 blockade is the most effective therapy for most 
patients with TRAPS, and the patient responded completely to this treatment further 
corroborating the disease phenotype.  
 
Materials and Methods 
 
Case report 
A 41 year old British man from non-consanguineous kindred with a history of recurrent 
fevers was referred to our clinic by an infectious diseases unit. He had presented after a 
period working in Asia and an extensive work up had demonstrated persistent inflammatory 
disease but no underlying infectious or autoimmune cause. On direct questioning he 
described previously undisclosed symptoms from early adolescence, including an 
appendectomy at the age of 12 in the context of severe abdominal pain. Since then he had had 
10 to 12 attacks of severe abdominal pain per year. These lasted approximately two weeks 
usually starting in either loin and migrating to the front of his abdomen. Other attack features 
included pleuritic chest pain, headache, arthralgia, myalgia, night sweats, generalised 
erythema and unilateral painless cervical lymphadenopathy. He had occasional red eyes but 
no periorbital oedema or periorbital pain. He was of normal population height, but 
significantly shorter than his siblings and had a late onset of puberty at 16 years of age. He 
reported that his attacks could be triggered by stress, cold, physical exercise and in some 
cases diet. Despite that, he was physically extremely fit and in full time employment. He had 
never received anti-inflammatory treatment. On examination he had bilateral red eyes and a 
generalised erythematous rash particularly across his chest.  He was tender over his left loin 
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with no features of peritonism, nor evidence of arthritis.  He had minor cervical 
lymphadenopathy. His inflammatory markers were extremely elevated with SAA 258 mg/L 
(normal range <10mg/l) and CRP 87 mg/L (normal range <10mg/l). His three siblings, 
parents and four children denied any similar symptoms. His clinical picture was consistent 
with TRAPS (7), thus genetic testing was performed. 
 
Methods 
 
Isolation of DNA  
DNA was extracted from whole blood, saliva, hair root and sperm using QIAamp DNA 
Investigator Kit (Qiagen, Velno, The Netherlands) according to the manufacturer’s protocol. 
In addition 20 ml of fresh whole blood was collected into EDTA tubes for isolation of T 
lymphocytes, B lymphocytes, monocytes and neutrophils using magnetic nanoparticles 
(Stemcell Technologies, Inc., Manchester, UK) following the manufacturer’s protocol. Purity 
of each cell subpopulation was determined by flow cytometry and was always >98% (data 
not shown). 
 
PCR and Sanger sequencing of TNFRSF1A 
TNFRSF1A gene (NCBI Reference Sequence:  NM_001065.3) exons 2 to 7 and introns  2, 4 
and 6 was amplified by PCR and sequenced with Big Dye Terminator v 3.1 Ready Reaction 
Cycle Sequencing kit (Applied Biosystems, Warrington, UK). The electropherograms were 
analysed on the ABI 3130xl Genetic Analyser using Sequencing Analysis Software version 
5.4. 
 
Allele-specific PCR of TNFRSF1A 
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Allele-specific (AS) PCR is used to discriminate between the wild type and mutant alleles 
relying on the complementarity of the primers. For TNFRSF1A gene forward wild type (5’-
GTGTGAGAGCGGCTCCT-3’) and forward mutant (5’-CTGCAGGGAGTGTGAAAAC-
3’) primers were designed. Their sequence was complementary to, and would only amplify 
the wild type and the mutant allele respectively (Figure 1D). DNA was amplified in two 
separate reactions using HotStarTaq DNA Polymerase Kit (Qiagen, Velno, The Netherlands): 
reaction 1 contained wild type primer and reaction 2 contained mutant primer, other reagents 
including the common reverse primer (5’-AACACACACCTTCCTGCC-3’) were identical in 
both reactions. The following cycling conditions were used: initial denaturation at 94oC for 
15 minutes, then 35 cycles consisting of denaturation at 94oC for 45 seconds, annealing at 
60oC for 45 seconds and extension at 72oC for 1 minute, followed by a single cycle of 72oC 
for 10 minutes.  The two amplicons containing wild type and mutant alleles were sequenced 
with a common reverse primer.  
 
Next- generation sequencing studies  
A targeted panel containing 19 genes associated with monogenic autoinflammatory diseases 
(Table 1 in Supplemental data)  was used to confirm  the TNFRSF1A deletion and to search 
for other pathogenic variants.  DNA was isolated from whole blood and amplified using the 
Agilent SureSelect Target Enrichment system. The QXT library generated from 50ng DNA 
input was sequenced on Illumina MiSeq platform. Data analysis was performed using the 
Galaxy Web-based suite as previously described (9). 
The MAF was established by amplicon-based deep sequencing (ADS) on DNA isolated from 
T lymphocytes, B lymphocytes neutrophils, monocytes, saliva, hair root and sperm. The 
amplicons of each DNA sample were obtained using a conventional PCR amplification, with 
the appropriate tags to identify each sample and sequenced on an IonTorrent platform. 
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Homology modeling of TNFR1 extracellular domain  
Detailed comparison of the native and variant TNFR1 proteins was performed by in silico 
molecular modeling focusing on the extracellular domain affected by the deletion. As a 
template we used the crystal structure of 1TNR (10) obtained from Protein Data Bank (online 
at http://www.rcsb.org/pdb/). The tertiary structure of the mutant TNFR1 was predicted from 
this template with ROSETTA 3.5 software (11); accuracy and resolution of the model was 
obtained with VADAR (12) and RESPROX (13) software. The quality and stereochemical 
correctness of the mutated receptor was assessed by Ramachandran plot. Mutated and native 
proteins were subjected to 20,000 steps of Steepest Sescent (SD) minimization algorithm and 
to 40,000 steps of Adopted Basis Newton-Raphson (ABNR) minimization algorithm. 
Visualization and analysis of each model were performed with VMD 1.9.2 program (14).  
    
Results 
 
Sanger sequencing, allele-specific (AS) PCR  
Sanger sequencing performed on DNA isolated from whole blood revealed an abnormal 
electropherogram in the exon 3 in the TNFRSF1A gene with the fluorescence peaks 
representing the mutant allele greatly reduced in comparison to wild type allele; nonetheless 
the sequence was suggestive of a large deletion (Figure 1A).  
Allele-specific (AS) PCR followed by Sanger sequencing of the specific amplicons revealed 
the c.255_278 deletion resulting in a novel in frame deletion of eight amino acids  
(p.Ser86_Glu93del according HGVS nomenclature recommendations, and p.Ser57_Glu64del 
according the ‘initial’ nomenclature as used in the Infevers database) (Figure 1B and 1C). 
Analysis of parental DNA by both Sanger and AS PCR revealed wild type TNFRSF1A 
genotype.  
Next-generation sequencing studies 
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Targeted sequencing confirmed the presence of the TNFRSF1A p.Ser86_Glu93 deletion 
(Figure 1E); no other pathogenic variants were found among the panel of 19 
autoinflammatory genes tested in our patient. The frequency of the mutant allele detected by 
amplicon-based deep sequencing in different cell subpopulations is displayed in Figure 1F.  
 
In silico molecular modeling 
Comparing the topology of extracellular domains of the wild type and the mutant TNFR1 we 
determined that the p.Ser86_Glu93 deletion resulted in lengthening of the mutated peptide 
from 66.90 Å (for the native) to 85.94 Å. The deletion reduced the minimization energy of 
the mutant receptor by 168 Kcal/mol compared to 1432 Kcal/mol in the wild type. 
Furthermore this mutation leads to numerous structural rearrangements (Supplement, Figure 
1), which result in changes of the protein surface profile, including shifts in the composition 
and structure of the three ligand-receptor binding pockets: p.Glu85_Cys102; 
p.Arg106_Gly110 and p.Trp136_Cys143 (Figure 2). The first of these three includes the 
residues p.Ser86_ Glu93 which are deleted by the mutation. 
 
Treatment  
The patient commenced treatment with s.c. anakinra (100 mg/day), to which he had a 
dramatic response with a resolution of all symptoms within 24 hours and normalization of 
SAA and CRP from median pre -treatment values of 171 mg/L and 35 mg/L to 8.1 mg/L and 
4 mg/L respectively. There was no adverse reaction to treatment and the patient has had 
sustained complete remission for 3.5 years on anakinra 100 mg administered on alternate 
days. Remarkably, this treatment period includes three months on a charitable race to the 
South Pole (Figure 3).  
Discussion 
 
Page 8 of 21
John Wiley & Sons
Arthritis & Rheumatology
This article is protected by copyright. All rights reserved.
We report the first case of TRAPS caused by a de novo mosaic deletion in the TNFRSF1A 
gene. The TNFRSF1A gene is located on chromosome 12p13 comprising 10 exons (1). Over 
100 pathogenic TRAPS causing mutations have been identified and most are single nucleotide 
substitutions (95%), although deletions and insertions have also been reported (15). One such 
example is the c.586_612del27 in-frame deletion of 27 nucleotides in exon 6, resulting in 
p.Leu196_Gly204del, found in a 22 year old man originating from Mauritius, who suffered 
with fever, severe abdominal pain and lymphadenopathy (16). His disease onset was at the 
age of 2 years, which rapidly progressed to amyloidosis with severe renal impairment 
requiring dialysis from age 19 years. His brother also suffered with AA amyloidosis and 
underwent renal transplantation at the age of 32 years (16).  
The novel mutation identified in our patient (c.255_278del) results in a deletion of 
eight amino acids p.Ser86_Glu93del from the cysteine-rich domain 2 (CRD2) (Figure 2), and 
is the second largest deletion reported in the TNFRSF1A gene. CRD2 consists of 41 amino 
acids and residues from Ser86 to Phe89 are structurally highly conserved (10). In particular, 
the hydrophobic Phe89 residue plays a crucial role in proper CRD2 folding, since its side 
chain stabilizes the structure by interacting with both the second disulfide bridge (formed 
between Cys102 and Cys117) and the Ser-103-Asp-122 hydrogen bond bridge (10). Using  in 
silico analyses we were able to show that the deletion introduces dramatic structural changes 
to the tertiary structure of TNFR1 extracellular domain including shifts of the receptor-ligand 
binding pockets. 
Mosaicism is characterized by presence of at least two genetically distinct populations 
of cells within one organism, arising from a post-zygotic mutation, and is well described in 
cancer and neurodegenerative diseases (17). Such de novo post-zygotic mutations may occur 
at any stage from early embryogenesis through adult life, and in the latter are likely to present 
in only restricted cell lines. Advances in sequencing have demonstrated that somatic 
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mosaicism is a feature of a number of dominantly inherited systemic autoinflammatory 
diseases, particularly in cryopyrin associated periodic fever syndrome (CAPS). Historically 
almost 50% of children with the most severe CAPS were ‘mutation negative’ by conventional 
Sanger sequencing, but it is now clear that up to 70% of such patients carry mosaic variants 
(9, 18, 19). A recent publication describes somatic NOD2 mosaicism causing Blau syndrome 
(20), another dominant autoinflammatory disease. 
The patient here described represents the first report of gonosomal TNFRSF1A 
mosaicism in TRAPS.  The 24 nucleotides deletion was detected in all tissues studied, 
including sperm, at varying frequencies from 4% to 30% (Figure 1).  The presence of the 
variant sequence in all cell lines indicates that the mutational event must have occurred at the 
very early stages of embryogenesis, probably during the pluripotent stage. Our patient’s 
parents were asymptomatic and both had wild-type TNFRSF1A genotypes sequence (data not 
shown),  confirming that the mutation occurred de novo. Almost certainly it is the mutation in 
the hematopoietic cells which are responsible for the clinical symptoms in our patient. As 
predicted for TRAPS he has achieved a complete clinical and serological response to IL-1 
blockade with anakinra. Importantly, the finding of a mutant allele frequency of 16% in his 
sperm raises the possibility of heritable disease and highlights the importance of discussing 
possible risks to offspring. 
 
Conclusion   
We describe a patient with TRAPS in whom we found a novel in-frame 24 nucleotide 
deletion by Sanger sequencing and AS-PCR. Next generation sequencing analyses revealed 
the post-zygotic nature of this novel mutation, and the studies of body distribution confirmed 
the first known case of gonosomal TNFRSF1A mosaicism.  Although proving pathogenicity 
of a novel mutation in a single case is challenging particularly in the absence of clear 
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functional consequences, extensive corroborative data including sequencing a panel of 19 
autoinflammatory genes and in silico modelling strongly suggest that this mutation is disease 
causing. Supporting this basic data, the symptoms and response to IL-1 blocking treatment 
were completely typical for TRAPS.  
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Figure 1. Partial DNA sequence of exon 3 of TNFRSF1A gene. A) DNA isolated from 
whole blood revealed the overlapping sequence of the mutant and the wild type alleles.  B) 
Wild type allele C) Mutant allele; were amplified independently by AS-PCR. The deleted 24 
nucleotides are shown in the box in panel B. D) Allele specific PCR showing the annealing 
location of each primer on the top to the wild type and the bottom to the mutant alleles of the 
TNFRSF1A gene. Top panel, the deleted sequence of 24 nucleotides from the wild type allele 
is shown in green. E) Illumina mapped reads from targeted NGS as visualized in Integrative 
Genomics Viewer (IGV), showing the TNFRSF1A c.255_278del as black line across the 
white bar, red and blue lines correspond to the forward and reverse mapped DNA sequence 
reads. F) Frequency of the mutant allele in different cell subpopulations.  
 
Figure 2.  In silico modeling of the extracellular domains of TNFR1. A) Four CRDs of 
the TNFR1 extracellular region: CRD1, CRD2, CRD3 and CRD4 shown in light brown, 
cyan, grey and orange respectively. The location of residues Ser86_Glu93 in the CRD2 is 
shown in red. B) Surface profile of native TNFR1 extracellular domain; C) – surface profile 
of mutated TNFR1. Red shading indicates ligand receptor–binding pocket Glu85-Cys102, 
blue shading - Arg106-Gly110, orange shading - Trp136- Cys143. The structural differences 
resulting from the eight amino acid deletion lead to the changes on the protein surface profile 
including the ligand receptor–binding pockets of TNFR1 extracellular domain.  
 
Figure 3. Low dose anakinra provided completely effective treatment of TRAPS even 
under the severe environmental stress of the Antarctic. Our patient under took a 920 mile 
unsupported expedition to the South Pole, pulling a 160 kg sledge containing 70 days of 
supplies including 40 syringes of anakinra, in an insulated container. 
 
Supplemental Figure 1. Influence of the Ser86_Glu93del mutation on the tertiary 
structure of TNFR1 extracellular domain. A) Native tertiary structure of TNFR1 
extracellular domain. B)  Tertiary structure of the variant receptor. C) Result of their 
alignment. Red color indicates the localization of rearrangements, black color -localization of 
mutation, orange color indicates amino acids located before and after deletion. 
 
 
Analysis of the native and mutated tertiary structures of TNFR1 extracellular domain showed 
that the Ser86_Glu93del mutation leads to structural rearrangements, such as: 1) transition of 
loop to α-helix in the position PRO52 –ASN54; 2) loop - β-sheet in the position SER56-
ILE57, which in its turn leads to elongation of β-sheet from position CYS58—LYS61 to 
SER56—LYS61; 3) loop - β-sheet in the positions GLN77-THR79 and CYS84, which in its 
turn leads to elongation of β-sheet from position ASP-80-CYS84 to GLN-77 – GLU83; 4) 
loop - β-sheet in the positions GLY110 – GLN111 and SER115 – SER116 which in its turn 
leads to elongation of β-sheet from position VAL112 – SER116 to GLY110 – SER115; 5) 
loop - β-sheet in the position THR123, which leads to elongation of β-sheet from position 
VAL124 – CYS127 to THR123 – CYS127; 6) loop - β-sheet in the positions ASN130 and 
SER137, which leads to elongation of β-sheet from GLN131 – TRP136 to ASN130 – 
SER137;   7) loop - β-sheet in the position ASN139 – LEU140, which leads to elongation of 
β-sheet from PHE141 – ASN145 to ASN139 – ASN145; 8) β-sheet - loop in the position 
Page 15 of 21
John Wiley & Sons
Arthritis & Rheumatology
This article is protected by copyright. All rights reserved.
SER157, which leads to shortening of β-sheet from GLY152 – SER157 to GLY152 – 
LEU156; 9) loop - β-sheet in the position THR164 and β-sheet – loop in the positions 
CYS168 – HIS169, which leads to shortening of β-sheet from VAL165 – HIS169 to THR164 
– THR167; 10) loop - β-sheet in the position GLY171 and β-sheet – loop in the position 
GLU176, which leads to displacement of β-sheet from PHE172 – GLU176 to GLY171 – 
ARG175; 11) β-sheet - loop in the positions GLU178 and CYS182, which leads to 
displacement of β-sheet from GLU178- CYS182 to ASN177 – SER181. 
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pocket Glu85-Cys102, blue shading - Arg106-Gly110, orange shading - Trp136- Cys143. The structural 
differences resulting from the eight amino acid deletion lead to the changes on the protein surface profile 
including the ligand receptor–binding pockets of TNFR1 extracellular domain.  
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Figure 3. Low dose anakinra provided completely effective treatment of TRAPS even under the severe 
environmental stress of the Antarctic. Our patient under took a 920 mile unsupported expedition to the 
South Pole, pulling a 160 kg sledge containing 70 days of supplies including 40 syringes of anakinra, in an 
insulated container.  
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